Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study

Published:2024-07 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Nikitas John¹^ORCID,Subramanian Kritika²,Gozal Nimrod Barashi³,Ricaurte-Fajardo Andres⁴^ORCID,Li Eric⁵^ORCID,Proudfoot James A.⁶,Davicioni Elai⁶^ORCID,Marciscano Ariel E.⁷^ORCID,Osborne Joseph R.⁴^ORCID,Barbieri Christopher E.⁸^ORCID,Armstrong Wesley R.⁹^ORCID,Smith Clayton P.¹^ORCID,Valle Luca F.¹¹⁰^ORCID,Steinberg Michael L.¹^ORCID,Boutros Paul C.¹¹^ORCID,Nickols Nicholas G.¹,Rettig Matthew B.¹²¹³^ORCID,Reiter Robert¹¹^ORCID,Weiner Adam B.¹¹¹⁴,Calais Jeremie⁹^ORCID,Czernin Johannes⁹,Ross Ashley Evan⁵^ORCID,Kim Eric H.¹⁵¹⁶^ORCID,Nagar Himanshu⁷,Kishan Amar U.¹¹¹^ORCID

Affiliation:

1. Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA

2. Department of Nuclear Medicine, New York-Presbyterian/Weill Cornell Hospital, New York, NY

3. Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO

4. Department of Radiology, New York-Presbyterian/Weill Cornell Hospital, New York, NY

5. Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL

6. Veracyte Inc, San Diego, CA

7. Department of Radiation Oncology, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY

8. Department of Urology, New York-Presbyterian/Weill Cornell Medical Center, New York, NY

9. Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA

10. Radiation Oncology Service, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA

11. Department of Urology, University of California, Los Angeles, Los Angeles, CA

12. Departments of Medicine and Urology, University of California, Los Angeles, Los Angeles, CA

13. Division of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA

14. Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA

15. Division of Urology, Department of Surgery, University of Nevada Reno School of Medicine, Reno, NV

16. Department of Physiology and Cell Biology, University of Nevada Reno School of Medicine, Reno, NV

Abstract

PURPOSE To characterize the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)–based metastatic spread. MATERIALS AND METHODS We identified patients from four institutions who underwent PSMA PET/CT scans pretreatment for primary staging or postradical prostatectomy (RP) for suspected recurrence and had Decipher transcriptomic data available from biopsy or RP specimens. PSMA PET/CT-based patterns of spread were classified as localized (miT + N0M0) or nonlocalized (miN1M0 or miM1a-c). We calculated the association between Decipher scores and the risk of nonlocalized disease on PSMA PET/CT using multivariable logistic regression for pretreatment patients and multivariable Cox regression for post-RP patients. We also compared select transcriptomic signatures between patients with localized and nonlocalized diseases. RESULTS Five hundred eighty-six patients were included (pretreatment: n = 329; post-RP: n = 257). Higher Decipher scores were associated with nonlocalized disease on PSMA PET/CT both pretreatment (odds ratio, 1.18 [95% CI, 1.03 to 1.36] per 0.1 increase in Decipher score, P = .02) and post-RP (hazard ratio, 1.15 [95% CI, 1.05 to 1.27] per 0.1 increase in Decipher score, P = .003). In the pretreatment setting, nonlocalized disease was associated with higher rates of TP53 mutations and lower rates of PAM50 luminal A subtype compared with localized disease. In the post-RP setting, overexpression of signatures related to metabolism, DNA repair, and androgen receptor signaling were associated with higher rates of nonlocalized disease. CONCLUSION Higher Decipher scores were associated with nonlocalized disease identified on PSMA PET/CT both pretreatment and post-RP. There were several transcriptomic differences between localized and nonlocalized diseases in both settings.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.24.00161

Reference13 articles.

1. A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy

2. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery

3. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens

4. Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy

5. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering Disease Profiles in the Era of Prostate-Specific Membrane Antigen Positron Emission Tomography: Aggressive or Indolent?;JCO Precision Oncology;2024-07